Alimera Sciences Inc Drug Patent Portfolio
Alimera Sciences Inc owns 2 orange book drugs protected by 10 US patents Given below is the list of Alimera Sciences Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7998108 | Injector apparatus and method of use | 12 Jan, 2028 | Active |
| US8871241 | Injectable sustained release delivery devices | 12 Aug, 2027 | Active |
| US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | 26 Apr, 2020 | Expired |
| US8574613 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | 26 Apr, 2020 | Expired |
| US8574659 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | 26 Apr, 2020 | Expired |
| US9192579 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | 26 Apr, 2020 | Expired |
| US9849085 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | 26 Apr, 2020 | Expired |
| US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | 27 Jun, 2019 | Expired |
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | 22 Mar, 2019 | Expired |
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | 22 Mar, 2019 | Expired |
Latest Legal Activities on Alimera Sciences Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alimera Sciences Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 01 Jan, 2024 | US9192579 |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US9192579 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Feb, 2023 | US7998108 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Apr, 2022 | US8871241 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 07 Apr, 2022 | US7998108 |
|
Expire Patent
Critical
| 31 Jan, 2022 | US9849085 |
|
Expire Patent
Critical
| 13 Dec, 2021 | US8574613 |
|
Expire Patent
Critical
| 13 Dec, 2021 | US8574659 |
|
Maintenance Fee Reminder Mailed
Critical
| 16 Aug, 2021 | US9849085 |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Jun, 2021 | US8574659 |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Jun, 2021 | US8574613 |
|
Expire Patent
Critical
| 05 Oct, 2020 | US8252307 |
|
Maintenance Fee Reminder Mailed
Critical
| 20 Apr, 2020 | US8252307 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 May, 2019 | US9192579 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 31 Jan, 2019 | US7998108 |
Alimera Sciences Inc's Family Patents
Alimera Sciences Inc drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 26.0% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alimera Sciences Inc Drug List
Given below is the complete list of Alimera Sciences Inc's drugs and the patents protecting them.
1. Iluvien
Iluvien is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8871241 | Injectable sustained release delivery devices |
12 Aug, 2027
(2 years from now)
| Active |
| US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
27 Jun, 2019
(5 years ago)
| Expired |
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iluvien's drug page
2. Yutiq
Yutiq is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7998108 | Injector apparatus and method of use |
12 Jan, 2028
(3 years from now)
| Active |
| US8871241 | Injectable sustained release delivery devices |
12 Aug, 2027
(2 years from now)
| Active |
| US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US8574613 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US8574659 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US9192579 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US9849085 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
26 Apr, 2020
(4 years ago)
| Expired |
| US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
27 Jun, 2019
(5 years ago)
| Expired |
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
22 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yutiq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List